Literature DB >> 31832843

Molecular Surveillance of Multidrug-Resistant Acinetobacter baumannii.

Aisha M AlAmri1, Ameerah M AlQurayan2, Tunny Sebastian3, Amani M AlNimr4.   

Abstract

Acinetobacter baumannii, a bacterial strain which demonstrates an elevated wide range multidrug resistance to commonly prescribed antibiotics, has been linked to recent major global outbreaks, raising a major clinical concern. Its reduced antibiotic susceptibility is closely related to the acquisition of a potent carbapenemase and/or intrinsic gene "over expression" through insertion sequences. Hence, this study aimed at investigating the antimicrobial susceptibility and molecular mechanisms underlying β-lactam resistance in A. baumannii, isolated at an academic medical centre. To understand the basis of resistance, 103 multidrug-resistant (MDR) A. baumannii isolates were collected, their antibiotic susceptibility was tested phenotypically, and then molecular analyses were performed, by testing a range of commonly encountered carbapenemases-OXA-51, OXA-23, NDM, VIM, and KPC. All strains demonstrated pan-resistance to most of the advanced antibiotics tested, including piperacillin/tazobactam, ceftazidime, cefepime, and ciprofloxacin. Moreover, majority of isolates exhibited resistance to imipenem (98.1%) and trimethoprim (90.3%). Approximately 50% of the strains showed meropenem, amikacin, and gentamycin resistance; however, lower resistance rate to tigecycline (4.9%) was noted. Moreover, isolates contained potent carbapenemases such as the intrinsic OXA-51 (89.3%), as well as the acquired resistant genes OXA-23 (68.9%), NDM (84.5%), and VIM (88.3%). The insertion sequence element ISAba1 was only detected in 35.9% of the strains. Potent resistant genes known to be carried on mobile genetic elements that aid the spread of highly resistant phenotypes were observed in a majority of isolates. These findings enforce the need for vigilant infection control measures and continuous surveillance.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31832843     DOI: 10.1007/s00284-019-01836-z

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  38 in total

1.  The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii.

Authors:  Jane F Turton; M Elaina Ward; Neil Woodford; Mary E Kaufmann; Rachel Pike; David M Livermore; Tyrone L Pitt
Journal:  FEMS Microbiol Lett       Date:  2006-05       Impact factor: 2.742

2.  Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents.

Authors:  Juliana Coelho; Neil Woodford; Mariya Afzal-Shah; David Livermore
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Microbiological and molecular detection of VIM-1 metallo beta lactamase-producing Acinetobacter baumannii.

Authors:  S M El-Ageery; S S Al-Hazmi
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

Review 4.  The rise of carbapenem-resistant Acinetobacter baumannii.

Authors:  Benjamin A Evans; Ahmed Hamouda; Sebastian G B Amyes
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 5.  Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis.

Authors:  Wentao Ni; Yuliang Han; Jin Zhao; Chuanqi Wei; Junchang Cui; Rui Wang; Youning Liu
Journal:  Int J Antimicrob Agents       Date:  2015-12-13       Impact factor: 5.283

6.  Detection of blaOXA-23-like and blaNDM-1 in Acinetobacter baumannii from the Eastern Region, Saudi Arabia.

Authors:  Taghrid S El-Mahdy; Mohamed H Al-Agamy; Ahmed A Al-Qahtani; Atef M Shibl
Journal:  Microb Drug Resist       Date:  2016-05-16       Impact factor: 3.431

7.  Prevalence of antimicrobial resistance among gram-negative isolates in an adult intensive care unit at a tertiary care center in Saudi Arabia.

Authors:  Sameera M Al Johani; Javed Akhter; Hanan Balkhy; Ayman El-Saed; Mousaad Younan; Ziad Memish
Journal:  Ann Saudi Med       Date:  2010 Sep-Oct       Impact factor: 1.526

8.  Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia.

Authors:  Essam J Alyamani; Mohamed A Khiyami; Rayan Y Booq; Basel M Alnafjan; Musaad A Altammami; Fayez S Bahwerth
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-08-20       Impact factor: 3.944

9.  Controlling endemic multidrug-resistant Acinetobacter baumannii in Intensive Care Units using antimicrobial stewardship and infection control.

Authors:  Shinhye Cheon; Mi-Ja Kim; Seon-Jin Yun; Jae Young Moon; Yeon-Sook Kim
Journal:  Korean J Intern Med       Date:  2016-02-15       Impact factor: 2.884

10.  High Prevalence of blaNDM-1, blaVIM, qacE, and qacEΔ1 Genes and Their Association with Decreased Susceptibility to Antibiotics and Common Hospital Biocides in Clinical Isolates of Acinetobacter baumannii.

Authors:  Fatma Alzahraa M Gomaa; Zeinab H Helal; Mazhar I Khan
Journal:  Microorganisms       Date:  2017-04-12
View more
  3 in total

Review 1.  Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace.

Authors:  Maria Soledad Ramirez; Robert A Bonomo; Marcelo E Tolmasky
Journal:  Biomolecules       Date:  2020-05-06

2.  Evaluating the Prevalence and the Risk Factors of Gram-Negative Multi-Drug Resistant Bacteria in Eastern Saudi Arabia.

Authors:  Aisha S Al Hamdan; Amal A Alghamdi; Ghada F Alyousif; Fatma A Hamza; Marwa M Shafey; Aisha M AlAmri; Abdulaziz A Sunki
Journal:  Infect Drug Resist       Date:  2022-02-17       Impact factor: 4.003

3.  Distribution of Carbapenemase Genes among Carbapenem-Non-Susceptible Acinetobacter baumanii Blood Isolates in Indonesia: A Multicenter Study.

Authors:  Dewi Anggraini; Dewi Santosaningsih; Yulia Rosa Saharman; Pepy Dwi Endraswari; Cahyarini Cahyarini; Leli Saptawati; Zinatul Hayati; Helmia Farida; Cherry Siregar; Munawaroh Pasaribu; Heriyannis Homenta; Enty Tjoa; Novira Jasmin; Rosantia Sarassari; Wahyu Setyarini; Usman Hadi; Kuntaman Kuntaman
Journal:  Antibiotics (Basel)       Date:  2022-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.